1. Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions 
Darius Sairafi, Mats Remberger, Michael Uhlin, Per Ljungman, Olle Ringdén, Jonas Mattsson 
Biology of Blood and Marrow Transplantation 
Volume 16, Issue 12, Pages (December 2010)
DOI: /j.bbmt
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Probability of survival in patients (pts) with early or late hematologic relapse after ASCT (at <365 days or >365 days, respectively). (B) Cumulative survival if DLI was given because of hematologic, molecular, or cytogenetic (only patients with chronic myeloid leukemia) relapse after ASCT. (C) Probability of survival in patients with acute leukemia and myelodysplastic syndrome (MDS) if DLI was given after hematologic or molecular relapse, the latter being ascertained mainly from chimerism analysis.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Chimerism analysis of leukemia-affected cell lineage in patients with acute lymphoblastic leukemia (ALL) who received DLI after ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Chimerism analysis of leukemia-affected cell lineage in patients with acute myelogenous leukemia (AML) who received DLI after ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Chimerism analysis of leukemia-affected cell lineage in patients with myelodysplastic syndrome (MDS) who received DLI after ASCT. In UPN 876 and 914, DLI was given after hematologic relapse.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions